Table 1.

Clinical and neuropathological characteristics of the NC subjects and AD patients

	Case no.	Age (years)^*	Gender	PMI (h)^*	ApoE allele	Clinical diagnosis	Disease duration (years)	MMSE score	Neuropathological summary	Brain weight (g)^**	CERAD plaque score	Braak staging
AD	AD-1	81	M	3	3/4	AD	13	6	AD	1090	Frequent	V
	AD-2	76	M	2.3	3/3	AD	11	0	AD, cerebral white matter rarefaction	1045	Frequent	VI
	AD-3	79	M	2	3/3	AD	7	0	AD, cerebral white matter rarefaction	1110	Frequent	V
	AD-4	90	F	3	3/3	AD, osteoarthritis, depression	11	5	AD, cerebral white matter rarefaction, hippocampal sclerosis	905	Frequent	V
	AD-5	89	F	3	3/4	AD	10	0	AD, cerebral white matter rarefaction in the frontal cortex	1010	Frequent	V
	AD-6	91	F	3	3/3	AD	6	0	AD, argyrophilic grains in the temporal cortex, acute infarctions in the right inferior temporal and occipital cortex	995	Frequent	V
NC	NC-1	85	M	3.2	3/3	Control	0	30	Control, old lacunar and microscopic infarcts in the left postcentral cortex	1280	None	II
	NC-2	86	F	2.5	3/3	Control, chronic lung fibrosis, rheumatoid arthritis	0	27	Control, recent small infarctions in the left frontal, left temporal cortex, old cortical microinfarction in the left precentral cortex, argyrophilic grains in mesial temporal cortex	1145	None	III
	NC-3	88	F	3	3/4	Control	0	30	Normal brain showing minimal age-related changes	1030	None	II
	NC-4	73	M	2	3/4	Control	0	28	Control, brain showing only normal aging changes	1410	None	II
	NC-5	86	F	2	2/3	Control, liver cancer, right leg thrombosis	0	29	Control, brain showing only normal aging changes	1150	None	II
	NC-6	78	M	1.7	3/3	Control	0	28	Control, cerebral white matter rarefaction and gliosis in the right temporal cortex	1460	None	I

M, Male; F, female; PMI, postmortem interval; MMSE, Mini-Mental State Examination; ApoE, apolipoprotein E.
↵*Not significantly different;
↵**p < 0.05 between AD and NC groups.